Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

FDA Approves Awiqli, Once-Weekly Insulin, for Children Aged 10 Years and Older With T2D

23 October 2026 · By · Wire by Fusion42

Published

23 October 2026

Topic

operational-macro

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at pharmacytimes.com →

◆ Verified

Fusion42 · 23 October 2026 · Fusion42 review

The FDA approved Awiqli (insulin icodec-abae), a once-weekly basal insulin injection, for children aged 10 years and older with type 2 diabetes, providing an alternative to daily injections and supported by clinical trials demonstrating efficacy and safety.

This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it.

◆ ◆ The Wire takeaway

You face a new chance to offer a basal insulin solution that reduces injection frequency for young T2D patients. This approval reopens pediatric diabetes treatment with an easier regimen to sell and build around.

◆ Coverage

2 sources · 23 Oct 2026

◆ Related on Wire

◆ Topics

Healthfda-approvalinsulinpediatric-diabetestype-2-diabetespharma-innovation